https://www.selleckchem.com/products/hg6-64-1.html
The discovery of immune checkpoints and their role in modulating immune response have revolutionised cancer treatment in recent years. The immune checkpoints, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) and its ligand, programmed cell death-ligand 1 (PD-L1), have been extensively studied. Currently seven monoclonal antibodies targeting these immune checkpoints are approved for treatment of various cancers. Inhibiting immune checkpoints has shown some success in clinic, however, a proport
Like
Comment
Share
